North Star Investment Management Has Trimmed Imax Com (IMAX) Position By $754,600; Shorts at Alliqua Biomedical DE (ALQA) Lowered By 3.84%

North Star Investment Management Corp decreased Imax Corp Com (IMAX) stake by 89.09% reported in 2017Q3 SEC filing. North Star Investment Management Corp sold 34,300 shares as Imax Corp Com (IMAX)’s stock declined 13.83%. The North Star Investment Management Corp holds 4,200 shares with $95,000 value, down from 38,500 last quarter. Imax Corp Com now has $1.32B valuation. The stock increased 1.00% or $0.2 during the last trading session, reaching $20.3. About 1.20M shares traded or 42.71% up from the average. IMAX Corporation (NYSE:IMAX) has declined 15.66% since February 5, 2017 and is downtrending. It has underperformed by 32.36% the S&P500.

Alliqua Biomedical DE (NASDAQ:ALQA) had a decrease of 3.84% in short interest. ALQA’s SI was 172,800 shares in February as released by FINRA. Its down 3.84% from 179,700 shares previously. With 73,700 avg volume, 2 days are for Alliqua Biomedical DE (NASDAQ:ALQA)’s short sellers to cover ALQA’s short positions. The stock decreased 2.38% or $0.05 during the last trading session, reaching $2.05. About 39,175 shares traded. Alliqua BioMedical, Inc. (NASDAQ:ALQA) has declined 66.38% since February 5, 2017 and is downtrending. It has underperformed by 83.08% the S&P500.

Investors sentiment decreased to 0.54 in 2017 Q3. Its down 1.17, from 1.71 in 2017Q2. It worsened, as 6 investors sold Alliqua BioMedical, Inc. shares while 7 reduced holdings. 3 funds opened positions while 4 raised stakes. 9.92 million shares or 8.64% less from 10.86 million shares in 2017Q2 were reported. Perceptive Advsrs Limited Liability Company reported 4.23 million shares stake. Virtu Fincl Ltd Liability Company reported 192,361 shares. Vanguard Inc has 0% invested in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Wells Fargo And Mn reported 428 shares stake. Citadel Advisors Ltd Liability holds 0% or 18,721 shares. Two Sigma Secs Limited Co stated it has 56,106 shares or 0% of all its holdings. Lpl Financial Ltd Liability reported 35,500 shares or 0% of all its holdings. Royal State Bank Of Canada holds 6,000 shares or 0% of its portfolio. Renaissance Technologies Ltd owns 980,600 shares for 0% of their portfolio. National Bank & Trust Of America De reported 97 shares. Ameriprise Fin Inc reported 0% stake. J Goldman L P, New York-based fund reported 450,000 shares. Jnba Financial Advsr stated it has 0% of its portfolio in Alliqua BioMedical, Inc. (NASDAQ:ALQA). Financial Bank Of Montreal Can, a Ontario – Canada-based fund reported 3,500 shares. Bank Of Ny Mellon Corporation reported 0% in Alliqua BioMedical, Inc. (NASDAQ:ALQA).

Among 3 analysts covering Alliqua Biomedical (NASDAQ:ALQA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Alliqua Biomedical has $10.0 highest and $1.5000 lowest target. $2.25’s average target is 9.76% above currents $2.05 stock price. Alliqua Biomedical had 12 analyst reports since August 19, 2015 according to SRatingsIntel. The company was maintained on Wednesday, February 24 by Chardan Capital Markets. The firm earned “Outperform” rating on Friday, November 6 by RBC Capital Markets. Chardan Capital Markets maintained the shares of ALQA in report on Friday, November 6 with “Buy” rating. On Friday, April 7 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Wednesday, January 3 by H.C. Wainwright. H.C. Wainwright maintained the shares of ALQA in report on Monday, November 2 with “Buy” rating. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, February 24. The firm earned “Neutral” rating on Monday, January 8 by H.C. Wainwright. The firm earned “Hold” rating on Wednesday, August 19 by Zacks. The stock of Alliqua BioMedical, Inc. (NASDAQ:ALQA) earned “Buy” rating by H.C. Wainwright on Wednesday, August 10.

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company has market cap of $10.22 million. It markets MIST Ultrasound Healing Therapy, a painless, noncontact, low-frequency ultrasound to promote healing; Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix that are human biologic regenerative technologies; and TheraBond 3D Antimicrobial Barrier Systems that promotes an optimal wound healing by creating an antimicrobial barrier that helps protect against infection. It currently has negative earnings. The firm also provides contract manufacturing services, including the development, manufacture, and market of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Analysts await IMAX Corporation (NYSE:IMAX) to report earnings on February, 22. They expect $0.34 earnings per share, up 161.54% or $0.21 from last year’s $0.13 per share. IMAX’s profit will be $22.02 million for 14.93 P/E if the $0.34 EPS becomes a reality. After $0.03 actual earnings per share reported by IMAX Corporation for the previous quarter, Wall Street now forecasts 1,033.33% EPS growth.

North Star Investment Management Corp increased Lilly Eli & Co Com (NYSE:LLY) stake by 4,900 shares to 14,050 valued at $1.20M in 2017Q3. It also upped Build A Bear Workshop Com (NYSE:BBW) stake by 153,100 shares and now owns 356,900 shares. Crown Crafts Inc Com (NASDAQ:CRWS) was raised too.

Among 18 analysts covering IMAX (NYSE:IMAX), 12 have Buy rating, 0 Sell and 6 Hold. Therefore 67% are positive. IMAX has $52 highest and $21.0 lowest target. $34.51’s average target is 70.00% above currents $20.3 stock price. IMAX had 55 analyst reports since July 21, 2015 according to SRatingsIntel. Macquarie Research maintained IMAX Corporation (NYSE:IMAX) on Wednesday, September 14 with “Outperform” rating. The firm has “Overweight” rating by JP Morgan given on Friday, October 27. Roth Capital maintained the shares of IMAX in report on Thursday, July 20 with “Buy” rating. M Partners maintained the stock with “Buy” rating in Wednesday, September 9 report. The firm earned “Neutral” rating on Wednesday, January 10 by PiperJaffray. The firm earned “Buy” rating on Tuesday, October 10 by Wedbush. M Partners maintained IMAX Corporation (NYSE:IMAX) on Wednesday, April 26 with “Buy” rating. Goldman Sachs maintained it with “Neutral” rating and $39 target in Friday, November 20 report. Roth Capital initiated the stock with “Buy” rating in Wednesday, July 20 report. Dougherty & Company maintained IMAX Corporation (NYSE:IMAX) rating on Friday, October 16. Dougherty & Company has “Buy” rating and $50.0 target.